Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19.
Antivir Ther
; 27(2): 13596535221082773, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1753060
ABSTRACT
If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk back to the last intersection and take another path, or one can consider taking few paths in parallel. The last scenario is reflective of the journey of remdesivir, the first antiviral for the treatment of COVID-19, that was approved by FDA less than 10 months after the isolation of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. As of January 2022, 10 million COVID-19 patients have been treated with remdesivir worldwide, but the journey of this molecule started more than a decade earlier with the search for a cure of hepatitis C virus. The development path of remdesivir before the emergence of COVID-19 represents a valuable example of a preemptive pandemic preparedness, but the pursuit of this path would not have been possible without sustaining support of John C. Martin, whom we will sorely miss for his piercing vision, uncompromising leadership, and genuine compassion for patients suffering around the world.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hepacivirus
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Antivir Ther
Journal subject:
Drug Therapy
/
Virology
Year:
2022
Document Type:
Article
Affiliation country:
13596535221082773
Similar
MEDLINE
...
LILACS
LIS